Holsapple M P
Hum Exp Toxicol. 2002 Sep-Oct;21(9-10):473-8. doi: 10.1191/0960327102ht284oa.
A workshop entitled 'Developmental Immunotoxicology and Risk Assessment' was held on 12-13 June 2001, in Washington, DC. The workshop was organized jointly by the Immunotoxicology Technical Committee (ITC) of the International Life Sciences Institute's (ILSI) Health and Environmental Sciences Institute (HESI) with input from the U.S. Environmental Protection Agency (EPA). Growing public concern that early exposure of the developing immune system to immunotoxic compounds may cause significant or persistent postnatal immunosuppression prompted the workshop. The main goal of the workshop was to examine scientific questions that underlie developmental immunotoxicity tests and the interpretation of the results as they relate to human risk assessment. A second goal was to provide a framework, based on current scientific knowledge, for the development of meaningful testing guidelines. The workshop focused on a series of questions that included how to address critical windows of exposure, how to develop and apply more predictive endpoints, does early chemical exposure cause transient or permanent effects on the immune system, as well as other related questions. On the first day, experts were invited to give scientific presentations relating to comparative developmental immunology, models of immunosuppression, and the regulatory aspects of developmental immunotoxicology. The second day was devoted to a panel discussion that included all the speakers as well as meeting participants, which attempted to answer each of the specific questions raised at the workshop. In general, it was acknowledged that there are a variety of techniques available for assessing immunosuppression in adult animal models, but there is uncertainty about how to apply these to a developing animal, especially if the goal is to have some standard procedure that can be applied for regulatory risk assessment. It was pointed out that although we know a lot about the developing immune system of individual species, we do not know how to relate the significance of drug or chemical effects on these systems in terms of human hazard. Overall, the panel deemed the area of developmental immunotoxicity to be still in its infancy and outlined strategies that could lead to the development of standard practices.
2001年6月12日至13日,一场名为“发育免疫毒理学与风险评估”的研讨会在华盛顿特区举行。该研讨会由国际生命科学研究所(ILSI)健康与环境科学研究所(HESI)的免疫毒理学技术委员会(ITC)联合组织,并得到了美国环境保护局(EPA)的支持。公众越来越担心发育中的免疫系统早期接触免疫毒性化合物可能会导致显著或持续的产后免疫抑制,这促使了本次研讨会的召开。研讨会的主要目标是探讨发育免疫毒性测试背后的科学问题,以及这些结果与人类风险评估相关的解读。第二个目标是基于当前的科学知识,为制定有意义的测试指南提供一个框架。研讨会聚焦于一系列问题,包括如何应对关键的暴露窗口期、如何开发和应用更具预测性的终点指标、早期化学暴露对免疫系统会产生短暂还是永久的影响,以及其他相关问题。第一天,邀请了专家就比较发育免疫学、免疫抑制模型以及发育免疫毒理学的监管方面进行科学演讲。第二天专门进行了小组讨论,所有演讲者和参会人员都参与其中,试图回答研讨会上提出的每一个具体问题。总体而言,大家承认在成年动物模型中评估免疫抑制有多种技术可用,但对于如何将这些技术应用于发育中的动物存在不确定性,特别是如果目标是要有一些可用于监管风险评估的标准程序。有人指出,尽管我们对单个物种发育中的免疫系统了解很多,但我们不知道如何将药物或化学物质对这些系统的影响在人类危害方面的意义联系起来。总体而言,小组认为发育免疫毒理学领域仍处于起步阶段,并概述了可能导致标准做法发展的策略。